As the world's largest provider of immunoassay systems and tests, with a market share that seems unassailable, Abbott Laboratories Inc. 's diagnostics business has fared comparatively well during a period of industry turmoil. But the $100 million consent decree it signed in early November with the Food and Drug Administration has left the diagnostics industry shaken.
As most people in diagnostics know by now, the FDA accuses Abbott of failing to comply with Good Manufacturing Practices and quality system regulation, despite repeated warnings. It ordered Abbott...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?